This is a five-year CCSG renewal (years 29-34) for the 231-member Jonsson Comprehensive Cancer Center at UCLA. Over the past five years, there have been extensive changes, including strengthening the leadership of the Program Areas with new appointments. The Division of Basic Sciences has added the recently formed Gene Regulation Program Area, and now consists of five Program Areas: 1) Signal Transduction; 2) Molecular, Cellular & Developmental Biology; 3) Tumor Immunology;4) Viral & Chemical Carcinogenesis; and 5) Gene Regulation. The Division of Cancer Prevention & Control Research hassubstantially strengthened its two Program Areas: 1) Healthy & At-Risk Populations; and 2) Patients & Survivors. The Division of Clinical/Translational Research has added the former developmental program area, Genitourinary Oncology (formerly Prostate Oncology), and now consistsof four Program Areas: 1) Women's Cancers; 2) Hematopoietic Malignancies & Bone MarrowTransplantation;3) Genitourinary Oncology; and 4) Cancer Therapy Development (formerly Solid Tumor Oncology). New Shared Resources are proposed, including Gene Expression Core, Immunology, Tissue Array, Bioinformatics, Mass Spectrometry & Proteomics, Small Animal Imaging, and Family & Genetic Evaluation. This gives a total of 14 Shared Resources, including those continuing from the previous funding period, Flow Cytometry, Nude/SCID Mouse, Media Prep, Transgenic Mouse/Embryonic Stem Cell, Human Tissue Research Center, the BASE Unit, and the Clinical Research Unit. Significant research accomplishments over the past funding cycle include our participation in the FDA approval of Herceptin and Gleevec. Cancer focus has been strengthened considerably, as evidenced by a doubling of the ratio of NCI dollars to number of JCCC members. The number of patients enrolled on cancer therapeutic trials has increased to 5,335 over the past five years, from 3,348 during the previous funding cycle. Finally, $5,594,251 in new cancer program awards has been received during the past 18 months, including an """"""""In Vivo Imaging Center"""""""" grant, a Director's Challenge Award, and a Lung SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016042-33S6
Application #
7684920
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1977-12-01
Project End
2009-04-01
Budget Start
2006-12-01
Budget End
2009-04-01
Support Year
33
Fiscal Year
2008
Total Cost
$113,837
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146
Waters, Lynnea R; Ahsan, Fasih M; Wolf, Dane M et al. (2018) Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling. iScience 5:99-109
Van Dyk, Kathleen; Bower, Julienne E; Crespi, Catherine M et al. (2018) Cognitive function following breast cancer treatment and associations with concurrent symptoms. NPJ Breast Cancer 4:25
Robinett, Ryan A; Guan, Ning; Lux, Anja et al. (2018) Dissecting Fc?R Regulation through a Multivalent Binding Model. Cell Syst 7:41-48.e5
Chin, Chee Jia; Li, Suwen; Corselli, Mirko et al. (2018) Transcriptionally and Functionally Distinct Mesenchymal Subpopulations Are Generated from Human Pluripotent Stem Cells. Stem Cell Reports 10:436-446
Alban, Tyler J; Alvarado, Alvaro G; Sorensen, Mia D et al. (2018) Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight 3:
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987

Showing the most recent 10 out of 767 publications